AbbVie (ABBV) to Acquire Apogee Therapeutics
Key takeaways
- Abb Vie (ABBV) to Acquire Apogee Therapeutics Noor Ul Ain Rehman Sun, June 28, 2026 at 2:21 AM GMT+7 1 min read ABBV APGE Abb Vie Inc.
- The company further stated that, according to the terms of the transaction, AbbVie Inc.
- While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.
Abb Vie (ABBV) to Acquire Apogee Therapeutics Noor Ul Ain Rehman Sun, June 28, 2026 at 2:21 AM GMT+7 1 min read ABBV APGE Abb Vie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. Abb Vie Inc. (NYSE:ABBV) and Apogee Therapeutics announced on June 22 their entry into a definitive agreement under which Abb Vie Inc. (NYSE:ABBV) will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across immunological and inflammatory diseases, which includes asthma and atopic dermatitis. Management stated that the acquisition complements the company's present immunology portfolio and bolsters its clinical presence in the respiratory space.
The company further stated that, according to the terms of the transaction, AbbVie Inc. (NYSE:ABBV) will acquire all outstanding shares of Apogee for $135.11 per share in cash, with the transaction valuing Apogee at a total equity value of approximately $10.9 billion. The transaction was unanimously approved by the boards of directors of both companies, and management expects the transaction to close in fiscal Q3 2026. This is subject to customary closing conditions, including Apogee shareholder approval and receipt of regulatory approvals.
AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.